Generex Biotechnology Stock Price, News & Analysis (OTCMKTS:GNBT)

$2.47 -0.43 (-14.83 %)
(As of 12/13/2017 03:41 AM ET)
Previous Close$2.92
Today's Range$2.32 - $2.92
52-Week Range$2.00 - $20.00
Volume4,371 shs
Average Volume3,198 shs
Market Capitalization$2.64 million
P/E RatioN/A
Dividend YieldN/A
Beta0.22

About Generex Biotechnology (OTCMKTS:GNBT)

Generex Biotechnology Corporation is a development-stage company. The Company is engaged in the research and development of drug delivery systems and technologies. The Company is involved in the development of a platform technology for the oral administration of large molecule drugs, including proteins, peptides, monoclonal antibodies, hormones and vaccines. The Company's subsidiary, Antigen Express, Inc. (Antigen), is engaged in research and development of technologies and immunomedicines for the treatment of malignant, infectious, autoimmune and allergic diseases. The Company holds interests in Hema Diagnostic Systems, LLC (Hema). Hema is in the business of developing, manufacturing, and distributing of in-vitro medical diagnostics for infectious diseases administered at the point of care level. Hema manufactures and sells rapid diagnostic devices based upon its own EXPRESS technology, as well as cassette devices based on customary designs used in the industry.

Receive GNBT News and Ratings via Email

Sign-up to receive the latest news and ratings for GNBT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Drug Delivery
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:GNBT
CUSIPN/A
Phone+1-416-3642551

Debt

Debt-to-Equity RatioN/A
Current Ratio0.12%
Quick Ratio0.12%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash Flow$16.47 per share
Price / Cash0.15
Book Value($74.78) per share
Price / Book-0.03

Profitability

Trailing EPS($68.29)
Net Income$-70,010,000.00
Net MarginsN/A
Return on Equity-25.84%
Return on Assets-77.52%

Miscellaneous

EmployeesN/A
Outstanding Shares1,070,000

Generex Biotechnology (OTCMKTS:GNBT) Frequently Asked Questions

What is Generex Biotechnology's stock symbol?

Generex Biotechnology trades on the OTCMKTS under the ticker symbol "GNBT."

When will Generex Biotechnology make its next earnings announcement?

Generex Biotechnology is scheduled to release their next quarterly earnings announcement on Wednesday, January, 17th 2018. View Earnings Estimates for Generex Biotechnology.

Who are some of Generex Biotechnology's key competitors?

Who are Generex Biotechnology's key executives?

Generex Biotechnology's management team includes the folowing people:

  • Mark A. Fletcher Esq, President, Chief Executive Officer, General Counsel, Director
  • Stephen Fellows, Chief Financial Officer
  • David A Brusegard Ph.D., Chief Operating Officer, Secretary
  • Andrew Greene, Director
  • Eric von Hofe Ph.D., Director (Age 59)
  • James H. Anderson Jr, M.D., Independent Director (Age 68)
  • Craig Eagle M.D., Independent Director (Age 55)
  • Gary Lyman M.D., Independent Director

How do I buy Generex Biotechnology stock?

Shares of Generex Biotechnology can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Generex Biotechnology's stock price today?

One share of Generex Biotechnology stock can currently be purchased for approximately $2.47.

How big of a company is Generex Biotechnology?

Generex Biotechnology has a market capitalization of $2.64 million. The company earns $-70,010,000.00 in net income (profit) each year or ($68.29) on an earnings per share basis.

How can I contact Generex Biotechnology?

Generex Biotechnology's mailing address is 10102 USA Today Way, MIRAMAR, FL 33025-3903, United States. The company can be reached via phone at +1-416-3642551 or via email at [email protected]


MarketBeat Community Rating for Generex Biotechnology (GNBT)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  27 (Vote Outperform)
Underperform Votes:  17 (Vote Underperform)
Total Votes:  44
MarketBeat's community ratings are surveys of what our community members think about Generex Biotechnology and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Generex Biotechnology (OTCMKTS:GNBT) Analyst Ratings History


No equities research coverage for this company has been tracked by MarketBeat

Earnings

Earnings History for Generex Biotechnology (OTCMKTS:GNBT)


No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Generex Biotechnology (OTCMKTS:GNBT) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Generex Biotechnology (OTCMKTS:GNBT)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Generex Biotechnology (OTCMKTS GNBT)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Generex Biotechnology (OTCMKTS GNBT) News Headlines

Source:
DateHeadline
Generex Announces Collaboration with Shenzhen BioScien Pharmaceuticals to Develop and Commercialize the AE37 Immunotherapeutic Vaccine for the Treatment of Prostate Cancer in ChinaGenerex Announces Collaboration with Shenzhen BioScien Pharmaceuticals to Develop and Commercialize the AE37 Immunotherapeutic Vaccine for the Treatment of Prostate Cancer in China
finance.yahoo.com - December 7 at 5:54 PM
Generex Announces Upgrade to OTCQB® Venture MarketGenerex Announces Upgrade to OTCQB® Venture Market
finance.yahoo.com - November 30 at 9:31 AM
Generex Announces Results of Annual Stockholders’ MeetingGenerex Announces Results of Annual Stockholders’ Meeting
finance.yahoo.com - November 27 at 5:39 PM
Generex Announces Exclusive Distribution Contract For Rapid 1-2-3® Hema HIV EXPRESS® in ChileGenerex Announces Exclusive Distribution Contract For Rapid 1-2-3® Hema HIV EXPRESS® in Chile
finance.yahoo.com - October 12 at 7:59 PM
Generex Announces New Clinical Trial of Hema Diagnostic Systems’ Rapid 1-2-3® Tuberculosis Point-of-Care TestsGenerex Announces New Clinical Trial of Hema Diagnostic Systems’ Rapid 1-2-3® Tuberculosis Point-of-Care Tests
finance.yahoo.com - September 20 at 3:53 PM
Generex Announces Order For Hema Diagnostic Systems Rapid 1-2-3® Hema HIV EXPRESS® In ChileGenerex Announces Order For Hema Diagnostic Systems' Rapid 1-2-3® Hema HIV EXPRESS® In Chile
www.thestreet.com - September 12 at 7:59 PM
Generex Announces Order for Hema Diagnostic Systems’ Rapid 1-2-3® Hema HIV EXPRESS® in ChileGenerex Announces Order for Hema Diagnostic Systems’ Rapid 1-2-3® Hema HIV EXPRESS® in Chile
finance.yahoo.com - September 12 at 7:59 PM
Generex Provides Summary of Ii-Key Hybrid Vaccine PlatformGenerex Provides Summary of Ii-Key Hybrid Vaccine Platform
finance.yahoo.com - August 7 at 6:52 PM
Generex Announces Collaboration with Merck to Evaluate KEYTRUDA® (pembrolizumab) in Combination with AE37 in Patients with Triple-Negative Breast CancerGenerex Announces Collaboration with Merck to Evaluate KEYTRUDA® (pembrolizumab) in Combination with AE37 in Patients with Triple-Negative Breast Cancer
finance.yahoo.com - July 31 at 6:44 PM
Generex Biotechnology Corporation (GNBT)Generex Biotechnology Corporation (GNBT)
finance.yahoo.com - July 9 at 11:13 PM
Generex Announces Reverse Stock Split - Business Wire (press release)Generex Announces Reverse Stock Split - Business Wire (press release)
www.businesswire.com - March 16 at 11:44 PM
GENEREX BIOTECHNOLOGY CORP Files SEC form 8-K, Unregistered Sale of Equity Securities, Financial Statements and ExhibGENEREX BIOTECHNOLOGY CORP Files SEC form 8-K, Unregistered Sale of Equity Securities, Financial Statements and Exhib
biz.yahoo.com - March 6 at 5:05 PM
GENEREX BIOTECHNOLOGY CORP Files SEC form 8-K, Material Modification to Rights of Security Holders, Other Events, FinGENEREX BIOTECHNOLOGY CORP Files SEC form 8-K, Material Modification to Rights of Security Holders, Other Events, Fin
biz.yahoo.com - February 16 at 5:24 PM
Hema Diagnostic Systems Announces the Initial Sale of Our Rapid 1-2-3(R) Hema Cassette Malaria PF/PV Through "WHO Procurement"Hema Diagnostic Systems Announces the Initial Sale of Our Rapid 1-2-3(R) Hema Cassette Malaria PF/PV Through "WHO Procurement"
us.rd.yahoo.com - January 25 at 9:48 PM
Yutaka Niihara, MD, MPH, CEO of Emmaus, Appointed Executive Chairman of Generex Biotechnology CorporationYutaka Niihara, MD, MPH, CEO of Emmaus, Appointed Executive Chairman of Generex Biotechnology Corporation
us.rd.yahoo.com - January 25 at 9:48 PM
Yutaka Niihara, MD, MPH, CEO of Emmaus, Appointed Executive Chairman of Generex Biotechnology Corporation - PR Newswire (press release)Yutaka Niihara, MD, MPH, CEO of Emmaus, Appointed Executive Chairman of Generex Biotechnology Corporation - PR Newswire (press release)
www.prnewswire.com - January 25 at 4:47 PM
ADDING MULTIMEDIA Generex Welcomes Dr. Yutaka Niihara, M.D., M.P.H. to Its Board of Directors - Business Wire (press release)ADDING MULTIMEDIA Generex Welcomes Dr. Yutaka Niihara, M.D., M.P.H. to Its Board of Directors - Business Wire (press release)
www.businesswire.com - January 25 at 4:47 PM
GENEREX BIOTECHNOLOGY CORP Files SEC form 8-K/A, Financial Statements and ExhibitsGENEREX BIOTECHNOLOGY CORP Files SEC form 8-K/A, Financial Statements and Exhibits
biz.yahoo.com - January 25 at 4:47 PM
Hema Diagnostic Systems Announces the Initial Sale of Our Rapid 1-2-3(R) Hema Cassette Malaria PF/PV Through ... - Baystreet.caHema Diagnostic Systems Announces the Initial Sale of Our Rapid 1-2-3(R) Hema Cassette Malaria PF/PV Through ... - Baystreet.ca
www.baystreet.ca - January 24 at 6:11 PM
Generex Announces Deal to Acquire Controlling Equity Interest in ... - Business Wire (press release)Generex Announces Deal to Acquire Controlling Equity Interest in ... - Business Wire (press release)
www.businesswire.com - January 24 at 6:11 PM
Generex Announces Closing of Acquisition of Controlling Equity ... - Business Wire (press release)Generex Announces Closing of Acquisition of Controlling Equity ... - Business Wire (press release)
www.businesswire.com - January 24 at 6:11 PM
Emmaus Life Sciences, Inc. Enters into Collaborative Agreement with Generex Biotechnology Corporation - PR Newswire (press release)Emmaus Life Sciences, Inc. Enters into Collaborative Agreement with Generex Biotechnology Corporation - PR Newswire (press release)
www.prnewswire.com - January 24 at 6:11 PM
GENEREX BIOTECHNOLOGY CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and EGENEREX BIOTECHNOLOGY CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E
biz.yahoo.com - January 20 at 6:47 PM

SEC Filings

Generex Biotechnology (OTCMKTS:GNBT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Generex Biotechnology (OTCMKTS:GNBT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Generex Biotechnology (OTCMKTS GNBT) Stock Chart for Wednesday, December, 13, 2017

Loading chart…

This page was last updated on 12/13/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.